

of U.S. Application No. 09/339,338, filed on June 23, 1999, which is a continuation-in-part of U.S. Application No. 09/285,480, filed on April 2, 1999, which is a continuation-in-part of U.S. Application No. 09/222,575, filed December 28, 1998.

In the claims:

Please cancel claims 4, 5, 7-12, 17-20, 39, 44-47, and 77-79.

Please amend claim 6 to read as follows:

6. (Amended) An isolated polynucleotide comprising at least the coding region of a sequence recited in SEQ ID NO:474.

Please add new claims 80-84 as follows:

80. (New) An isolated polynucleotide comprising a sequence selected from the group consisting of:

- (a) complements of the sequence provided in SEQ ID NO:474;
- (b) sequences consisting of at least 20 contiguous nucleotides of a sequence provided in SEQ ID NO:474;
- (c) sequences that hybridize to a sequence provided in SEQ ID NO:474, under moderately stringent conditions;
- (d) sequences having at least 75% identity to a sequence of SEQ ID NO:474;
- (e) sequences having at least 90% identity to a sequence of SEQ ID NO:474; and
- (f) degenerate variants of a sequence provided in SEQ ID NO:474;

wherein said polynucleotide is over-expressed in breast tissue as compared to normal tissue.

81. (New) An expression vector comprising a polynucleotide of claim 6 or claim 80 operably linked to an expression control element.

82. (New) A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component comprising a polynucleotide according to claim 6 or claim 80.